# US 9,750,751 B2 · Hypotensive lipid-containing biodegradable intraocular implants and related methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,750,751 B2
- Document ID: US9750751B2
- Status: Granted
- Kind: B2
- Application number: 15/211,242
- Filed: 2016-07-15
- Published: 2016-11-10
- Granted: 2017-09-05
- Earliest claimed: 2004-04-30
- Assignees: Allergan, Inc.
- Applicants: Allergan, Inc.
- Inventors: Patrick M. Hughes
- Web page: https://patentgrep.com/patent/US9750751B2

## CPC

- A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A61F 9/0017: {implantable in, or in contact with, the eye, e.g. ocular inserts}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0051: {Ocular inserts or implants}
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/10: for accommodation disorders, e.g. myopia
- A61P 27/12: for cataracts
- A61P 27/14: Decongestants or antiallergics
- A61P 27/16: Otologicals
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 9/204: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.

## Claims

### Claim 1

A method of treating glaucoma, the method comprising placing a biodegradable intraocular implant into the anterior chamber of an eye of a patient in need thereof, the implant comprising latanoprost and a biodegradable polymer matrix that releases an amount of the latanoprost from the implant effective to reduce at least one symptom of glaucoma, wherein the amount of the latanoprost is released into the eye for a period of time greater than about one week to less than about six months after the implant is placed into the anterior chamber of the eye.

### Claim 2 (depends on 1)

The method of claim 1, wherein the symptom is increased intraocular pressure in the eye.

### Claim 3 (depends on 1)

The method of claim 1, wherein the biodegradable polymer matrix comprises a polylactic acid polymer.

### Claim 4 (depends on 3)

The method of claim 3, wherein the biodegradable polymer matrix further comprises a polylactic acid polyglycolic acid copolymer.

### Claim 5 (depends on 4)

The method of claim 4, wherein the method is effective in maintaining the intraocular pressure in the eye at a reduced level.

### Claim 6 (depends on 4)

The method of claim 4, wherein the method is effective in reducing intraocular pressure in the eye.

### Claim 7 (depends on 4)

The method of claim 4, wherein the symptom is increased intraocular pressure in the eye.

### Claim 8 (depends on 2)

The method of claim 2, wherein the implant is injected into the anterior chamber of the patient with a needle.

### Claim 9 (depends on 4)

The method of claim 4, wherein the implant is injected into the anterior chamber of the patient with a needle.